查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464700

同种异体细胞治疗市场：按类型、应用和最终用途 - 2024-2030 年全球预测

Allogeneic Cell Therapy Market by Type, Application, End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

异体细胞治疗市场规模预计2023年为20.4亿美元，2024年达23.1亿美元，预计2030年将达到50.8亿美元，复合年增长率为13.90%。

同种异体细胞疗法是一种医疗程序，将来自一名健康捐赠者的细胞移植到多名患者体内，以帮助治疗多种疾病，包括某些癌症、自体免疫疾病和心臟病。基因工程、细胞加工和培养技术的进步显着提高了同种异体细胞疗法的功效和安全性，推动了市场成长。癌症、自体免疫疾病和心血管疾病在全球的盛行率不断上升，推动了对同种异体细胞疗法等创新治疗方法的需求。在全球范围内，有利的政府政策和细胞治疗方法研究资金的增加正在加速市场扩张。然而，开发和实施同种异体细胞疗法的高昂成本限制了更广泛的患者群体的使用。需要免疫抑制剂来避免免疫排斥和副作用仍然是市场成长的主要挑战。此外，旨在改善细胞来源、储存和扩充性的持续研究为市场成长提供了巨大的机会。开发适合个别患者情况的同种异体细胞治疗解决方案可能为个人化医疗开闢新途径。

主要市场统计
基准年[2023] 20.4亿美元
预测年份 [2024] 23.1亿美元
预测年份 [2030] 50.8亿美元
复合年增长率（%） 13.90%

发炎和免疫调节作用扩大了间质干细胞疗法的采用

嵌合体抗原受体T细胞疗法（CAR-T）是引入特异性标靶癌细胞的嵌合体抗原受体，提供个人化的癌症治疗方法。 CAR-T细胞疗法主要用于某些类型的血癌，包括非何杰金氏淋巴瘤和急性淋巴性白血病，以改善治疗结果。造血干细胞移植涉及移植供体（异体）的干细胞，以健康的干细胞取代受损的骨髓。当其他治疗方法无效时，造血干细胞移植是某些白血病、淋巴瘤和遗传性血液疾病患者治疗方法计画的一部分。诱导性多功能干细胞疗法 (iPSC) 是将皮肤和血球重新编程为胚胎样多功能状态。 iPSC技术主要应用于再生医学、疾病模型和药物发现。间质干细胞疗法具有分化成各种细胞类型的能力，并具有发炎和免疫调节作用。

应用：彻底改变其在改善同种异体细胞疗法和器官移植手术中的作用

同种异体细胞疗法大大改善了白血病和淋巴瘤等血液疾病的治疗。在肿瘤治疗中，同种异体细胞疗法利用免疫系统攻击癌细胞的能力，用于对抗多种癌症。

再生医学是同种异体细胞疗法中最令人兴奋的领域，专注于修復、替换和再生人体细胞、器官和组织以及恢復正常功能。同种异体细胞疗法在固态器官移植中也发挥关键作用，特别是在降低移植排斥风险和终生免疫抑制的需求方面。

区域洞察

美洲，特别是美国和加拿大，在强劲投资、尖端研究和日益促进生物技术创新的法规环境的推动下，处于同种异体细胞治疗行业的前沿。智慧财产权的发展，例如细胞处理技术和反应器设计专利的稳定取得，显示了美洲地区市场的活力。在欧盟（EU），政府和私人对再生医学（包括异体细胞疗法）给予了强烈的支持。德国、英国和法国等国家尤其活跃，开展了大量临床试验和研究倡议，并从鼓励创新同时确保病人安全的法律规范中受益。阿拉伯联合大公国和沙乌地阿拉伯等中东国家正大力投资医疗基础设施，并表示有兴趣引进先进的医疗方法，包括细胞疗法。非洲地区更加多元化，南非在再生医学的研究和兴趣方面处于领先地位。在亚太地区，中国在政府对生物技术研究的大力支持下正在取得显着进展。日本和印度享有再生医学先驱的声誉，并得到有利的监管政策的支持，以快速开发有前景的治疗方法。

FPNV定位矩阵

FPNV定位矩阵对于评估同种异体细胞治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对同种异体细胞治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，以获得市场竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.同种异体细胞治疗市场的市场规模与预测是多少？

2.在同种异体细胞治疗市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.同种异体细胞治疗市场的技术趋势和法规结构是什么？

4.同种异体细胞治疗市场主要厂商的市场占有率是多少？

5. 进入同种异体细胞治疗市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症、自体免疫疾病和心血管疾病的发生率增加
      • 有利的政府政策和增加细胞治疗方法研究资金
    • 抑制因素
      • 同种异体细胞疗法开发和管理的复杂法规环境
    • 机会
      • 开发个人化同种异体细胞治疗解决方案
      • 探索神经退化性疾病和心臟病的新治疗方法
    • 任务
      • 免疫排斥和相容性问题
  • 市场区隔分析
    • 类型：间间质干细胞疗法因其发炎和免疫调节特性而被越来越多地采用
    • 应用：彻底改变同种异体细胞疗法在器官移植治疗和改善中的作用
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章同种异体细胞治疗市场：依类型

  • 嵌合体抗原受体T细胞疗法
  • 造血干细胞移植
  • 诱导性多功能干细胞治疗
  • 间质干细胞治疗

第七章同种异体细胞治疗市场：依应用分类

  • 血液疾病
  • 肿瘤学
  • 再生医学
  • 固态器官移植

第八章同种异体细胞治疗市场：依最终用途

  • 生物技术和製药公司
  • 医院/诊所
  • 调查机构

第九章美洲同种异体细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太同种异体细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲同种异体细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争场景分析
    • Getinge 与 CellRev 之间的策略合作伙伴关係彻底改变了製造业
    • 开创性协议将促进全球获得 StemCyte 突破性的脐带血衍生细胞疗法
    • Gamida Cell 的 Omisirge 疗法核准FDA 批准，成为血癌治疗的突破
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-CA100284D019

[187 Pages Report] The Allogeneic Cell Therapy Market size was estimated at USD 2.04 billion in 2023 and expected to reach USD 2.31 billion in 2024, at a CAGR 13.90% to reach USD 5.08 billion by 2030.

Allogeneic cell therapy involves medical treatments wherein cells are transferred from a single healthy donor to multiple patients to help treat various diseases, including certain cancers, autoimmune diseases, and heart conditions. Ongoing advances in genetic engineering, cell processing, and culturing techniques have significantly enhanced the efficacy and safety of allogeneic cell therapies, fueling market growth. The growing incidence of cancers, autoimmune diseases, and cardiovascular conditions globally drives the demand for innovative treatments such as allogeneic cell therapy. Favorable government policies worldwide and increased funding for research in cell-based therapies have accelerated market expansion. However, high costs associated with the development and administration of allogeneic cell therapies limit accessibility for a broader patient base. Immune rejection and the need for immunosuppressants to avoid adverse reactions remain significant challenges for market growth. Moreover, continuous research aiming at improving cell sourcing, preservation, and scalability presents substantial opportunities for market growth. Developing tailored allogeneic cell therapy solutions catering to individual patient profiles may open new avenues for personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 2.04 billion
Estimated Year [2024] USD 2.31 billion
Forecast Year [2030] USD 5.08 billion
CAGR (%) 13.90%

Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties

Chimeric antigen receptor T cell therapy (CAR-T) involves the introduction of a chimeric antigen receptor that specifically targets cancer cells, providing a personalized approach to cancer therapy. CAR-T cell therapy is primarily employed for certain types of blood cancers including non-Hodgkin lymphoma and acute lymphoblastic leukemia for improved outcomes. Hematopoietic stem cell transplantation is responsible for the transplantation of stem cells from a donor (allogeneic) to replace damaged bone marrow with healthy stem cells. Hematopoietic stem cell transplantation is the treatment of choice for patients with certain leukemias, lymphomas, and genetic blood disorders when other treatments are not effective or as a part of the treatment plan. Induced pluripotent stem cell therapy (iPSC) is derived from skin or blood cells reprogrammed back into an embryonic-like pluripotent state. iPSC technology is primarily utilized for regenerative medicine, disease modeling, and drug discovery. Mesenchymal stem cell therapy has the ability to differentiate into various cell types and possesses anti-inflammatory and immunomodulatory properties.

Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures

Allogeneic cell therapy has significantly improved the treatment of hematological disorders, such as leukemia and lymphoma. In oncology therapies, allogeneic cell therapy is utilized to fight against various cancer forms, leveraging the immune system's capacity to attack cancer cells.

Regenerative medicine represents the most exciting areas of allogeneic cell therapy, focusing on repairing, replacing, and regenerating human cells, organs, or tissues to restore normal function. Allogeneic cell therapy also plays a pivotal role in solid organ transplantation, particularly in reducing the risk of transplant rejection and the need for lifelong immunosuppression.

Regional Insights

The Americas, particularly the United States and Canada, are at the forefront of the allogeneic cell therapy industry, driven by robust investments, cutting-edge research, and a supportive regulatory environment that is increasingly conducive to innovation in biotechnology. Intellectual property developments, typified by a steady stream of patents related to cell processing techniques and bioreactor designs, demonstrate the vibrancy of the market in the Americas region. The European Union observes strong government and private support for regenerative medicine, including allogeneic cell therapy. Countries such as Germany, the United Kingdom, and France have been particularly active, with numerous clinical trials and research initiatives, and also benefit from a regulatory framework encouraging innovation while ensuring patient safety. Middle East countries such as the United Arab Emirates and Saudi Arabia, are investing significantly in healthcare infrastructure and have shown interest in adopting advanced medical treatments, including cell therapies. The African region is more diverse, with South Africa leading in terms of research and interest in regenerative medicine. In the APAC region, China has made remarkable strides, with substantial government backing for biotechnology research. Japan and India have a well-established reputation for pioneering regenerative medicine, supported by favorable regulatory policies to fast-track promising therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Allogeneic Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Allogeneic Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Chimeric Antigen Receptor T Cell Therapy
    • Hematopoietic Stem Cell Transplantation
    • Induced Pluripotent Stem Cell Therapy
    • Mesenchymal Stem Cell Therapy
  • Application
    • Hematological Disorders
    • Oncology
    • Regenerative Medicine
    • Solid Organ Transplantation
  • End-Use
    • Biotechnology & Pharmaceutical Companies
    • Hospitals & Clinics
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Allogeneic Cell Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Allogeneic Cell Therapy Market?

3. What are the technology trends and regulatory frameworks in the Allogeneic Cell Therapy Market?

4. What is the market share of the leading vendors in the Allogeneic Cell Therapy Market?

5. Which modes and strategic moves are suitable for entering the Allogeneic Cell Therapy Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
      • 5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of personalized allogeneic cell therapy solutions
      • 5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Immune rejection and compatibility issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
    • 5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Allogeneic Cell Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Chimeric Antigen Receptor T Cell Therapy
  • 6.3. Hematopoietic Stem Cell Transplantation
  • 6.4. Induced Pluripotent Stem Cell Therapy
  • 6.5. Mesenchymal Stem Cell Therapy

7. Allogeneic Cell Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Hematological Disorders
  • 7.3. Oncology
  • 7.4. Regenerative Medicine
  • 7.5. Solid Organ Transplantation

8. Allogeneic Cell Therapy Market, by End-Use

  • 8.1. Introduction
  • 8.2. Biotechnology & Pharmaceutical Companies
  • 8.3. Hospitals & Clinics
  • 8.4. Research Institutes

9. Americas Allogeneic Cell Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Allogeneic Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Allogeneic Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
    • 12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
    • 12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ALLOGENEIC CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ALLOGENEIC CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ALLOGENEIC CELL THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 73. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 74. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 88. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 112. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 118. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 130. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 142. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 186. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 198. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 210. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 222. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 246. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 258. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 270. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 289. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 290. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023